Newspaper Publication of the Audited Financial Results of the Company for the Quarter and Year ended 31st March, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Fredun Pharmaceuticals Ltd has published its audited financial results for Q4 and FY 2025-26 in Active Times and Mumbai Lakshadeep newspapers on 27th May 2026. The results were approved by the Board of Directors on 25th May 2026 in compliance with SEBI Listing Regulation 47(1)(b). The filing includes a newspaper clipping of financial statements showing Total Revenue of Rs. 593.67 lakhs for Q4 FY26 versus Rs. 818.13 lakhs in Q4 FY25, and Total Revenue of Rs. 3,109.32 lakhs for FY26 versus Rs. 4,626.60 lakhs in FY25. Profit After Tax turned negative at Rs. (168.84) lakhs for Q4 FY26 compared to Rs. 168.94 lakhs profit in Q4 FY25. Full year PAT was Rs. (302.82) lakhs against profit of Rs. 242.13 lakhs in the previous year. EPS declined from Rs. 1.27 in FY25 to Rs. (2.01) in FY26. NOTE: The newspaper clipping enclosed with this filing appears to show financial data for Ekansh Concepts Limited (CIN: L74110MH1992PLC070070), not Fredun Pharmaceuticals - this appears to be an error in the filing enclosure.
The financial results indicate a significant deterioration in performance with the company reporting losses in both Q4 and full FY 2025-26, with revenue declining by approximately 33% year-on-year. Shareholders should note the shift from profit to loss-making status and the substantial revenue contraction.